

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

CSPC MEGALITH BIOPHARMACEUTICAL CO., LTD.,

Petitioner,

v.

SHANGHAI MIRACOGEN INC.,

Patent Owner.

---

Case No. IPR2025-00685

U.S. Patent No. 10,792,370

---

**PATENT OWNER'S UPDATED EXHIBIT LIST**

**PATENT OWNER’S UPDATED EXHIBIT LIST**

<b>Exhibit No.</b>	<b>Description</b>
2001	International Nonproprietary Names for Pharmaceutical Substances, WHO Drug Information, Vol. 38, No. 2, 2024
2002	Fei Han et al., Becotatug vedotin vs. chemotherapy in pre-heavily treated advanced nasopharyngeal carcinoma: A randomized, controlled, multicenter, open-label study
2003	Lepu Biopharma Co., Ltd., Voluntary Announcement, Breakthrough Therapy Designation Granted by the FDA to MRG003 for the Treatment of R/M NPC
2004	U.S. Food & Drug Administration, Fast Track
2005	U.S. Food & Drug Administration, Breakthrough Therapy
2006	EGFR expression in normal human tissues (HPA RNA-seq normal tissues) - <a href="https://www.ncbi.nlm.nih.gov/gene/1956">https://www.ncbi.nlm.nih.gov/gene/1956</a>
2007	CD30 expression in normal human tissues (HPA RNA-seq normal tissues) - <a href="https://www.ncbi.nlm.nih.gov/gene/943">https://www.ncbi.nlm.nih.gov/gene/943</a>
2008	European Patent Application No. EP4434549A1
2009	CSPC Pharmaceutical Group Limited Voluntary Announcement, May 19, 2025
2010	Lu S. et al., “Abstract CT008: First-in-human study of SYS6010, a novel EGFR targeting antibody drug conjugate (ADC) for patients with advanced solid tumors,” <i>Cancer Res</i> (2025) 85 (8_Supplement_2): CT008
2011	International Publication No. WO2012/100346A1
2012	Huang L. et al., “Abstract 1217: Preclinical evaluation of a next-generation, EGFR targeting ADC that promotes regression in KRAS or BRAF mutant tumors,” <i>Cancer Res.</i> (2016) 76 (14_Supplement): 1217

2013	Phillips AC et al., “Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate,” <i>Mol Cancer Ther</i> ; 17(4) April 2018 795-805
2014	Carneiro B. et al., “Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma,” <i>Neuro-Oncology Advances</i> 5(1), 1–12, 2022
2015	U.S. Patent Application Publication No. 2011/0076232 (“Old-232”)
2016	AbbVie, A Study Evaluating Safety and Pharmacokinetics of ABB-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor. ClinicalTrials.gov Identifier NCT02365662 (March 30, 2018)
2017	Lepu Biopharma Co. Ltd. 2024 Annual Report
2018	Written Opinion of the International Searching Authority for WO2023/088382
2019	Conference Transcript for Proceedings on December 2, 2025

Date: December 9, 2025

Respectfully,

SHEPPARD, MULLIN,  
RICHTER & HAMPTON LLP

*/ Christopher Ponder /*

Christopher Ponder (Reg. No. 77,167)

Alex Nie (Reg. No. 60,523)

Fangzhou Qiu (Reg. No. 82,810)

Attorneys for Patent Owner  
Shanghai Miracogen Inc.

**CERTIFICATE OF SERVICE**

The undersigned hereby certifies that, on this date, a complete copy of the foregoing Patent Owner's Updated Exhibit List was served via email to all parties to this proceeding at the addresses indicated:

Joe G. Chen, Ph.D. (joechen@foxrothschild.com)

Howard S. Suh (hsuh@foxrothschild.com)

Ryan N. Miller (rmiller@foxrothschild.com)

ipdocket@foxrothschild.com

Date: December 9, 2025

/ Christopher Ponder /

Christopher Ponder